3D tissue-engineered bone marrow for personalized therapy and drug development
A tissue-engineered bone marrow for personalized therapy of a patient is described. The tissue-engineered bone marrow includes an autologous fibrin scaffold and a plurality of patient-derived cells isolated from the patient's bone marrow. The autologous fibrin scaffold is made using fibrinogen isolated from the patient's bone marrow. The plurality of patient-derived cells may include cells associated with a hematological or metastatic malignancy, bone marrow stromal cells, and endothelial cells. The patient-derived cells are cultured on the autologous fibrin scaffold to create the tissue-engineered bone marrow. The tissue-engineered bone marrow may be used for personalized drug screening.
1. A method of drug screening using a prepared tissue-engineered bone marrow for personalized therapy of a patient comprising:
applying a drug at a dose to the tissue-engineered bone marrow, the tissue-engineered bone marrow comprising:
an autologous fibrin scaffold comprising fibrinogen isolated from the patient's bone marrow; and
a plurality of patient-derived cells isolated from the patient's bone marrow, the patient-derived cells selected from the group consisting of cells associated with a hematological or metastatic malignancy, bone marrow stromal cells, endothelial cells, and combinations thereof,
wherein the patient-derived cells are cultured on the autologous fibrin scaffold; and
predicting the drug response in the patient based on the effectiveness of the drug and the dose in the tissue-engineered bone marrow.
2. The method of claim 1 , wherein the autologous fibrin scaffold further comprises a patient-derived culture compound extracted from the patient's bone marrow, the patient-derived culture compound selected from the group consisting of: fibronectin, at least one growth factor, platelets, at least one cytokine, at least one enzyme, and combinations thereof.
3. The method of claim 1 , wherein the autologous fibrin scaffold further comprises a gradient of oxygen and the drug.
4. The method of claim 1 , wherein the cells associated with a hematological or metastatic malignancy are selected from acute lymphoblastic leukemia cells, acute myelogenous leukemia cells, chronic lymphocytic leukemia cells, acute monocytic leukemia cells, Hodgkin's lymphoma cells, non-Hodgkin's lymphoma cells, multiple myeloma cells, metastatic cells, and solid tumor cells.
5. The method of claim 1 , wherein the effectiveness of the drug and the dose is determined by drug uptake by the plurality of cells or cell death of the cells associated with a hematological or metastatic malignancy.
6. The method of claim 1 , wherein predicting the drug response in the patient comprises determining patient specific drug resistance.
7. The method of claim 1 , wherein the patient has a disease selected from the group consisting of hematologic malignancies, multiple myeloma, and bone metastasis of solid tumors.